Lymphocyte development and lymphoid disorders
Posted by
supportmlcom
on 20 February 2024
Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signalling demonstrate preclinical efficacy and safety in Multiple Myeloma.
Roders N, Nakid-Cordero C, Raineri F, Fayon M, Abecassis A, Choisy C, Nelson E, Maillard C, Garrick D, [...]
Read morePosted by
filipe@mlcom.fr
on 8 June 2023
Distinct subsets of multi-lymphoid progenitors support ontogeny-related changes in human lymphopoiesis.
Keita S, Diop S, Lekiashvili S, Chabaane E, Nelson E, Strullu M, Arfeuille C, Guimiot F, Domet T, Duchez S, [...]
Read morePosted by
filipe@mlcom.fr
on 16 March 2023
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A*, Talbot A*, Perrot A, Cazaubiel T, Leleu X, Manier S, Buisson L, Mahéo S, Do Souto [...]
Read morePosted by
filipe@mlcom.fr
on 8 December 2022
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study.
Debureaux PE, Harel S, Parquet N, Lemiale V, Siguret V, Goubeau L, Morin F, Royer B, Cuccuini W, Elessa D, [...]
Read morePosted by
filipe@mlcom.fr
on 7 December 2022
Applications of Non-Coding RNAs in Multiple Myeloma Patients.
Zocchi S, David A, Goodhardt M, Garrick D. Nature: Clinical Applications of Non-Coding RNAs in Cancer. [...]
Read morePosted by
filipe@mlcom.fr
on 21 June 2022
CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment.
Abecassis A, Roders N, Fayon M, Choisy C, Nelson E, Harel S, Royer B, Villesuzanne C, Talbot A, Garrick D, [...]
Read morePosted by
filipe@mlcom.fr
on 19 June 2022
Inflammatory Waldenström’s macroglobulinaemia: A French monocentric retrospective study of 67 patients.
Elessa D, Debureaux PE, Villesuzanne C, Davi F, Bravetti C, Harel S, Talbot A, Oksenhendler E, Malphettes [...]
Read morePosted by
filipe@mlcom.fr
on 7 March 2022
The Sec61 translocon is a therapeutic vulnerability in multiple myeloma.
Domenger A, Choisy C, Baron L, Mayau V, Perthame E, Deriano L, Arnulf B, Bories JC, Dadaglio G, Demangel C. [...]
Read morePosted by
supportmlcom
on 30 September 2021
The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling
David A, Zocchi S, Talbot A, Choisy C, Ohnona A, Lion J, Cuccuini W, Soulier J, Arnulf B, Bories JC, [...]
Read morePosted by
filipe@mlcom.fr
on 1 June 2021
Clinical Applications of Non-Coding RNAs in Cancer
Keita S, Canque B, Alhaj Hussen K. Nature:Methods Mol Biol. 2021;2308:225-233. Link: [...]
Read more